long intergenic non-protein coding RNA 1863Genealiases: []
Q-omics provides the consensus-scored LINC01863 profile across patient tissues and cancer cell-line models. LINC01863 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, LINC01863 is differentially expressed in 9, with the highest sampling consensus in LUAD. Additionally, LINC01863 RNA expression shows 7,948 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight COAD, LUAD, and BRCA as cancer lineages where LINC01863 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01863 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01863 survival associations across molecular data types. LINC01863 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01863 RNA expression–survival associations across cancer types. High LINC01863 expression shows unfavorable associations in COAD, CHOL, LUSC and ACC, but favorable associations in BRCA and HNSC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for LINC01863 RNA expression.
This table summarizes LINC01863 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01863. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01863 shows lower tumor expression in LUAD, KIRP, LUSC, KIRC and LIHC and higher tumor expression in BRCA. The LUAD box plot shows higher LINC01863 RNA expression in normal versus tumor tissue (log2 FC = −2.590, t-test p < 0.001).
This table shows molecular features associated with LINC01863 in patient tissues and cancer cell lines. In patient samples, LINC01863 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
